Retatrutide is not FDA approved and is not available through any legal prescription channel in the United States. It cannot be legally compounded or prescribed outside of authorized clinical trials. This retatrutide guide is for informational purposes only. If you're looking for available GLP-1 programs, see our program comparison page covering 17 independently reviewed options.
What is retatrutide? A 2026 guide to the triple agonist
This retatrutide guide starts with the basics: retatrutide (LY3437943) is an investigational once-weekly injectable drug developed by Eli Lilly. It is the first drug to simultaneously activate three gut hormone receptors — GLP-1, GIP, and glucagon. Every approved GLP-1 medication currently on the market activates one or two of these receptors. Retatrutide activates all three, which is why researchers, clinicians, and patients are paying close attention as 2026's Phase 3 data has begun reporting.
Semaglutide (Wegovy, Ozempic) is a single GLP-1 agonist. Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor activation on top of both, which increases energy expenditure and accelerates hepatic fat clearance in ways the other two cannot.
How it works — the triple agonist difference
Understanding retatrutide requires understanding what each receptor does:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, improves insulin sensitivity, and promotes glucose-dependent insulin secretion. This is the mechanism shared by semaglutide and tirzepatide.
- GIP receptor: Enhances insulin secretion, may improve fat metabolism, and appears to amplify the weight loss effect of GLP-1 activation. Tirzepatide was the first approved drug to add this.
- Glucagon receptor: Increases energy expenditure and accelerates hepatic (liver) fat clearance. This is retatrutide's addition — and the primary reason for its superior weight loss numbers. Glucagon activation burns more calories and clears liver fat more aggressively than the GLP-1 and GIP mechanisms alone.
The result is a drug that hits appetite, insulin sensitivity, energy expenditure, and liver fat simultaneously — the most comprehensive metabolic mechanism of any obesity drug tested in Phase 3 trials to date.
Retatrutide Guide: Phase 3 Data — Two Trials Now Complete
As of June 2026, Eli Lilly has reported two successful Phase 3 readouts from the TRIUMPH program: TRIUMPH-4 in December 2025, and TRIUMPH-1 — the pivotal general-obesity trial — on May 21, 2026. Both met their primary and key secondary endpoints.
TRIUMPH-4: obesity + knee osteoarthritis
TRIUMPH-4 was a 68-week randomized, double-blind, placebo-controlled study in 445 adults with obesity and knee osteoarthritis. It was the first Phase 3 obesity trial to demonstrate significant improvement in both body weight and joint pain simultaneously.
28.7% mean body weight loss at 68 weeks on the 12mg dose.
71.2 lbs average lost on the 12mg dose. More than 1 in 4 pounds of baseline body weight.
~95% of participants achieved at least 5% weight loss — the FDA's threshold for clinical meaningfulness.
75.8% reduction in knee pain scores (WOMAC scale) — a secondary endpoint no obesity drug had demonstrated before.
Study population: 445 adults with BMI ≥27 and knee osteoarthritis. All results vs. placebo.
TRIUMPH-1: the pivotal general-obesity trial
TRIUMPH-1 is the largest trial in the program and the one expected to carry the primary weight-management NDA. Announced May 21, 2026, it enrolled 2,339 adults with obesity or overweight and at least one weight-related comorbidity — hypertension, dyslipidemia, sleep apnea, or osteoarthritis — but no diabetes. Participants were randomized 1:1:1:1 to 4mg, 9mg, 12mg, or placebo over 80 weeks, with step-wise dose escalation starting at 2mg.
19.0% weight loss (47.2 lbs) at the 4mg dose, with just a single dose-escalation step.
23.7%–25.9% weight loss at the 9mg dose, depending on reporting source (64.4 lbs).
25.0%–28.3% weight loss at the 12mg dose at 80 weeks — vs. 3.9% on placebo.
Up to 30.3% weight loss (85.0 lbs) in participants with baseline BMI ≥35 who continued into the 104-week extension — the highest figure recorded for retatrutide to date.
Cardiometabolic improvements were also significant: waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and hsCRP all improved from baseline.
How it compares to approved medications
| Medication | Mechanism | Phase 3 weight loss | Trial duration | Status |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% (STEP-1) | 68 weeks | FDA approved 2021 |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual | ~20.9% (SURMOUNT-1) | 72 weeks | FDA approved 2023 |
| Retatrutide | GLP-1 + GIP + glucagon | 25–30.3% (TRIUMPH-1, 12mg) | 80 weeks | Phase 3 — not approved |
The trajectory is clear: each generation of GLP-1 class drugs has produced meaningfully higher weight loss than the last. Retatrutide's results now confirmed across two independent Phase 3 trials begin to approach the 25–35% range typically seen with bariatric surgery — without surgery.
Retatrutide dosing — what Phase 3 actually tested
This retatrutide guide focuses on clinical trial dosing, not self-administered or compounded protocols — retatrutide cannot legally be compounded or prescribed outside trials in the US. The table below reflects the dose-escalation schedule used in TRIUMPH-1.
| Trial dose | Weight loss at 80 weeks | Escalation steps |
|---|---|---|
| 4 mg weekly | 19.0% (47.2 lbs) | Single step from 2mg |
| 9 mg weekly | 23.7%–25.9% (64.4 lbs) | Step-wise from 2mg, every 4 weeks |
| 12 mg weekly | 25.0%–28.3% | Step-wise from 2mg, every 4 weeks |
| 12 mg, 104-wk extension (BMI ≥35) | Up to 30.3% (85.0 lbs) | Continued from 80-week cohort |
The slow, step-wise titration is consistent with how semaglutide and tirzepatide are dosed — gradual escalation reduces GI side effects and improves tolerability. No retatrutide dosing chart exists for clinical prescribing because no approved label exists yet. Any "dosing guide" or reconstitution chart you find online referring to research-grade or gray-market retatrutide is not based on an approved prescribing standard, and using such products carries real risk — see below.
The TRIUMPH Phase 3 program — 6 readouts still to come
TRIUMPH-1 and TRIUMPH-4 are two of eight Phase 3 trials in Eli Lilly's TRIUMPH program, which has enrolled more than 5,800 participants — one of the largest Phase 3 programs for any obesity medication in history, plus a separate roughly 10,000-patient cardiovascular outcomes trial. Six additional trial readouts are expected throughout the remainder of 2026.
Side effects — what's different from semaglutide and tirzepatide
Retatrutide shares the GI side effect profile common to all GLP-1 class medications — nausea, diarrhea, vomiting, and constipation — consistent with what patients experience on semaglutide and tirzepatide. These are generally mild and concentrated in early weeks of dose escalation.
What's distinct about retatrutide is a side effect not seen with other GLP-1 medications: dysesthesia — an abnormal skin sensation described as tingling, sensitivity, or tenderness to the touch. In TRIUMPH-4, approximately 20.9% of patients on the 12mg dose experienced dysesthesia. Most cases were mild and rarely led to discontinuation.
Overall discontinuation rates due to adverse events were 12.2% on the 9mg dose and 18.2% on the 12mg dose, compared to 4.0% on placebo. These rates were notably higher in patients with BMI ≥35. For context, tirzepatide discontinuation rates in SURMOUNT-1 were approximately 7%. This is an area regulators will scrutinize closely during review, and TRIUMPH-1's safety data will add meaningfully to this picture once fully published.
FDA approval timeline — realistic expectations
- One or more of the six remaining TRIUMPH trials failing to meet primary endpoints
- FDA requesting additional safety data on dysesthesia or discontinuation rates, which were notably elevated vs. tirzepatide
- Manufacturing or supply chain issues scaling production
- Regulatory review queue delays — the FDA is processing multiple obesity drug submissions concurrently
Why you can't get it now — and what to watch for
As of June 2026, retatrutide cannot legally be prescribed, compounded, or purchased in the United States outside of clinical trial participation. The FDA has not approved it for any indication. No telehealth platform can legally offer it.
This matters because some gray-market and offshore sources are already advertising retatrutide — frequently labeled "for research use only." These products have unknown purity, unknown dosing accuracy, and zero regulatory oversight. The FDA has previously indicated that even research peptide vendors selling retatrutide for "research use only" operate in legally ambiguous territory when their products are administered to humans. The strong Phase 3 results reported this year have, if anything, increased gray-market interest — which makes this caution more relevant now than it was in April, not less.
If you're interested in retatrutide, the most productive steps are to bookmark this guide for updates, sign up for our email list to be notified when it becomes available, and in the meantime evaluate the proven options that are available today. Semaglutide and tirzepatide are both producing meaningful, well-characterized results — and the programs offering them have improved significantly in 2026.
No spam. Unsubscribe any time.
What's available right now
While retatrutide works through clinical trials toward FDA approval, semaglutide and tirzepatide are producing results that would have seemed extraordinary five years ago. For most adults with significant weight loss goals, the gap between tirzepatide and retatrutide is smaller than the gap between doing nothing and starting tirzepatide today.
Compounded GLP-1 programs bring the cost of these medications from $1,000–$1,400/month at retail pharmacies down to $119–$299/month through licensed telehealth platforms — a meaningful difference that makes treatment accessible without insurance.
Medical disclaimer: This retatrutide guide is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved by the FDA. It cannot legally be prescribed or compounded outside of authorized clinical trials in the United States. Trial results cited are from Eli Lilly press releases and subsequent peer-reviewed and trade-press coverage, including reporting from AJMC, Pharmacy Times, and the Pharmaceutical Journal. Where sources reported differing figures for the same dose, we presented the range rather than a single number. Timelines are estimates based on current information and subject to change. Consult a licensed physician before beginning any weight loss medication program.